SEKISUI CHEMICAL has sold SEKISUI XENOTECH to BioIVT, a portfolio company of Linden Capital Partners

SEKISUI XENOTECH

Headquartered in Kansas City, Kansas, SEKISUI XENOTECH (SXT) has almost 30 years of experience as a contract research organization specializing in absorption, distribution, metabolism and excretion (ADME), drug metabolism and pharmacokinetics (DMPK) and drug-drug interactions (DDIs) testing of potential drug candidates. Utilized by top pharmaceutical companies, biotechnology firms and other organizations, SXT provides the tools and resources to advance the development of effective and safe drugs.

By helping SXT’s clients understand as much as possible about their drugs, they have the best chance of getting to clinical trials, and ultimately to the market where patients may benefit. SXT has pursued synergies by expanding the service offering through knowledge sharing from SEKISUI MEDICAL, a 100% subsidiary of SEKISUI CHEMICAL, and by seeking to develop new customers in Europe and the United States.

The Deal

SXT’s product lines will complement BioIVT’s portfolio of hepatocytes and other hepatic products. SXT’s expertise also combines well with BioIVT’s strengths in drug transporter research, B-CLEAR® disposition studies, long-term HEPATOPAC® models and other proprietary methodologies and will increase BioIVT’s capabilities to support and accelerate customer research.

SEKISUI MEDICAL will continue its drug development solutions business after the sale of SXT and in the future expand beyond the area of pharmacokinetics. By providing a broad set of drug development solutions, SEKISUI MEDICAL will support the research and development in pharmaceutical companies aiming to realize its vision of creating “a healthy and sustainable world.”

Our Perspective

This transaction was evidence of the rapid globalization of the clinical trial business and the growing importance of capabilities around pre-clinical and non-clinical drug development. Shahab Fatheazam, Vice Chairman in Lincoln’s Healthcare Group, added, “Having been familiar with the XenoTech asset, I found this transaction to be very noteworthy. First, it is emblematic of the opportunities for Japanese companies to re-orient their assets in the U.S. and secondly, it is another example of the growth and consolidation in the pre-clinical drug development sector.” BioIVT is now better poised to deliver a broader menu of services to its customers in their pursuit of drug metabolisms in compounds and their effects on disease processes.

BioIVT

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. BioIVT specializes in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids.

Share: